For how we live.
In 120 older adults with acute myeloid leukaemia, adding midostaurin to two-drug therapy did not raise remission rates overall (72% vs 68%), but a small FLT3-mutated subgroup lived longer.
In the 172-patient PARADIGM trial, azacitidine plus venetoclax more than doubled median event-free survival versus induction chemotherapy — but it was a phase 2 study not powered for overall survival.
In the phase 3 BRUIN CLL-322 trial, adding pirtobrutinib to a fixed course of venetoclax and rituximab raised 24-month progression-free survival to 87% from 72% in previously treated disease.
Beqalzi (sonrotoclax) is approved for relapsed mantle-cell lymphoma after a BTK inhibitor. Just over half of 103 patients responded in a single-arm trial with no survival data.